David M Spencer
Overview
Explore the profile of David M Spencer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
3180
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wu C, Hong S, Winkler T, Spencer D, Jares A, Ichwan B, et al.
Mol Ther Methods Clin Dev
. 2015 Jun;
1:14053.
PMID: 26052521
Induced pluripotent stem cell (iPSC) therapies offer a promising path for patient-specific regenerative medicine. However, tumor formation from residual undifferentiated iPSC or transformation of iPSC or their derivatives is a...
12.
Zhou X, Dotti G, Krance R, Martinez C, Naik S, Kamble R, et al.
Blood
. 2015 May;
125(26):4103-13.
PMID: 25977584
To test the feasibility of a single T-cell manipulation to eliminate alloreactivity while sparing antiviral and antitumor T cells, we infused 12 haploidentical hematopoietic stem cell transplant patients with increasing...
13.
Barese C, Felizardo T, Sellers S, Keyvanfar K, Di Stasi A, Metzger M, et al.
Stem Cells
. 2014 Oct;
33(1):91-100.
PMID: 25330775
The high risk of insertional oncogenesis reported in clinical trials using integrating retroviral vectors to genetically modify hematopoietic stem and progenitor cells (HSPCs) requires the development of safety strategies to...
14.
Kemnade J, Seethammagari M, Collinson-Pautz M, Kaur H, Spencer D, McCormick A
Vaccine
. 2014 Jun;
32(33):4228-33.
PMID: 24923637
Over the past 20 years, dendritic cells (DCs) have been utilized to activate immune responses capable of eliminating cancer cells. Currently, ex vivo DC priming has been the mainstay of...
15.
Zhou X, Di Stasi A, Tey S, Krance R, Martinez C, Leung K, et al.
Blood
. 2014 Apr;
123(25):3895-905.
PMID: 24753538
Adoptive transfer of donor-derived T lymphocytes expressing a safety switch may promote immune reconstitution in patients undergoing haploidentical hematopoietic stem cell transplant (haplo-HSCT) without the risk for uncontrolled graft versus...
16.
Budde L, Berger C, Lin Y, Wang J, Lin X, Frayo S, et al.
PLoS One
. 2013 Dec;
8(12):e82742.
PMID: 24358223
Modification of T cells with chimeric antigen receptors (CAR) has emerged as a promising treatment modality for human malignancies. Integration of co-stimulatory domains into CARs can augment the activation and...
17.
Carstens J, Shahi P, Van Tsang S, Smith B, Creighton C, Zhang Y, et al.
Cancer Res
. 2013 Dec;
74(2):609-20.
PMID: 24305876
The reactive stroma surrounding tumor lesions performs critical roles ranging from supporting tumor cell proliferation to inducing tumorigenesis and metastasis. Therefore, it is critical to understand the cellular components and...
18.
Valdez J, Zhang L, Su Q, Dakhova O, Zhang Y, Shahi P, et al.
Cell Stem Cell
. 2012 Nov;
11(5):676-88.
PMID: 23122291
The role of Notch signaling in the maintenance of adult murine prostate epithelial homeostasis remains unclear. We found that Notch ligands are mainly expressed within the basal cell lineage, while...
19.
Spencer D
Oncoimmunology
. 2012 Jun;
1(3):362-363.
PMID: 22737615
To better control the "licensing" of pro-Th1 dendritic cells (DCs), Spencer and colleagues have developed a synthetic ligand-inducible chimeric receptor, iMyD88/CD40 (iMC), incorporating synergistic Toll-like receptor (TLR) and costimulatory signaling...
20.
Kemnade J, Seethammagari M, Narayanan P, Levitt J, McCormick A, Spencer D
Mol Ther
. 2012 Mar;
20(7):1462-71.
PMID: 22434138
Recent modest successes in ex vivo dendritic cell (DC) immunotherapy have motivated continued innovation in the area of DC manipulation and activation. Although ex vivo vaccine approaches continue to be...